Printer Friendly

SEARLE AND WYETH-AYERST DISCUSS CO-PROMOTION OF MAXAQUIN(R)

 SEARLE AND WYETH-AYERST DISCUSS CO-PROMOTION OF MAXAQUIN(R)
 CHICAGO and PHILADELPHIA, May 1 /PRNewswire/ -- Searle and Wyeth- Ayerst are discussing co-promotion of Searle's new quinolone antibacterial agent, Maxaquin(R) (lomefloxacin HCl) in the United States.
 Maxaquin, which was approved for marketing in the United States in February of this year, is the first one-tablet, once-a-day, broad spectrum quinolone for all its labelled indications.
 The arrangement under discussion may include provision for Searle to co-promote a near-term Wyeth-Ayerst compound.
 Searle is a research-based pharmaceutical company that develops, manufactures and markets prescription pharmaceuticals worldwide in the areas of cardiovascular, gastrointestinal, anti-inflammatory, anti- infective and central nervous system. It is a wholly owned subsidiary of Monsanto Company (NYSE: MTC).
 Wyeth-Ayerst is a division of American Home Products Corporation (NYSE: AHP), a worldwide manufacturer and marketer of prescription drugs, medical supplies and diagnostics, over-the-counter medicines and food products. The Wyeth Ayerst division is a major research-oriented pharmaceutical company with leading products in the areas of female health care, cardiovascular and metabolic disease therapies, central nervous system drugs, anti-inflammatory agents, vaccines and infant nutritionals.
 /delval/
 -0- 5/1/92
 /CONTACT: Kim Piekos of Searle, 708-470-6716, or Audrey Ashby of Wyeth-Ayerst, 215-971-5823/
 (MTC AHP) CO: Searle; Wyeth-Ayerst Laboratories ST: Pennsylvania, Illinois IN: MTC SU: JVN


MP-MK -- PH002 -- 5301 05/01/92 08:29 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 1, 1992
Words:218
Previous Article:MEDSTAT SYSTEMS ANNOUNCES RECORD SECOND-QUARTER RESULTS
Next Article:OPTA FOOD INGREDIENTS, INC. REPORTS FIRST QUARTER FINANCIAL RESULTS


Related Articles
FIRST ONE-TABLET, ONCE-A-DAY QUINOLONE FOR ALL INDICATIONS ENTERS $5.1 BILLION U.S. ANTI-INFECTIVE MARKET
AMERICAN HOME PRODUCTS CORP. AND KAKEN PHARMACEUTICAL ANNOUNCE GROWTH HORMONE LICENSING AGREEMENT
BURROUGHS WELLCOME CO. AND WYETH-AYERST TO CO-PROMOTE NEW TREATMENT FOR CHICKENPOX
SEARLE AND WYETH-AYERST TO CO-PROMOTE MAXAQUIN
SEARLE AND WYETH-AYERST CO-PROMOTE ONLY ONCE-A-DAY QUINOLONE ANTIBIOTIC
RUSSIA APPROVES FIST ONCE-A-DAY QUINOLONE FOR ANTI-INFECTIVE USE
SEARLE DONATES $500,000 OF MAXAQUIN (LOMEFLOXACIN HCL) TO RUSSIAN FOUNDATION
Searle, Unimed Reach Agreement On U.S. Marketing And Distribution Rights For Maxaquin
CoCensys Licenses Novel Anxiety Treatment to Wyeth-Ayerst
Scios and Wyeth-Ayerst Terminate Co-Promotion Agreement for Antidepressant Drug, Effexor(R)

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters